At its 19th annual An Evening of Hope & Healing gala, Cancer Support Community San Francisco Bay Area (CSC) will honor Michael M. Morrissey, Ph.D., President and CEO of Exelixis (NASDAQ: EXEL), with the Spirit of Hope award. The award is given each year to a Bay Area resident who has made significant contributions to the field of cancer patient care—through their hard work, their exemplary philanthropy, or their outstanding leadership.
Dr. Morrissey joined Exelixis in 2000 and, after holding several positions of increasing responsibility within the company, took on the role of President and CEO in 2010. Under Dr. Morrissey’s leadership since July 2010, the Exelixis team has brought to market three internally discovered medicines aimed at improving the treatment of various forms of cancer, significantly expanded the company’s clinical development and commercial capabilities and markedly strengthened the company’s financial position in order to prepare for the next chapter of its growth.
In 2018, Exelixis moved into brand new, state-of-the-art facilities in Alameda, California, and immediately reached out to CSC with the goal of helping local cancer patients get the critical, holistic care needed to help them recover stronger and live longer. Through a charitable contribution and sponsorship of CSC’s 2018 gala, Exelixis enabled CSC to provide free programs and services to many Bay Area residents, helping them achieve their best possible medical outcomes and their greatest quality of life while facing cancer. In 2019 under Dr. Morrissey’s leadership, the company is continuing its support of CSC while also broadening its philanthropic support of other patient care organizations.
“On behalf of Exelixis, I am honored to receive the 2019 Spirit of Hope award from the Cancer Support Community San Francisco Bay Area,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. “Exelixis is on a mission to help cancer patients recover stronger and live longer. We value our partnership with the Cancer Support Community and believe that together we have an opportunity to improve patients’ lives through integrated care. We commend the organization for their dedication to providing a wide array of comprehensive services to thousands of people impacted by cancer in the Bay Area.”
CSC invites the community to attend the gala on September 28, 2019, at the Blackhawk Auto Museum in Danville, California. For information about attending or sponsoring the gala, contact Carol Louisell, Director of Development at 925.953.1209.
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.